Ulta CEO Proves Weight Loss Drugs Are Just a Beauty Store Stimulus Plan

KEY POINTS

•Ulta Beauty CEO Kecia Steelman revealed on October 14, 2025, that GLP-1 drugs have increased demand for specific beauty products.
•About 10% of Americans use GLP-1 weight loss drugs, with many buying hair loss and skin elasticity treatments to combat side effects.
•In 2025, Ulta Beauty’s sales climbed to $12.39 billion, with haircare and skincare sales surging as rapid weight loss trends reshape the market.

On October 14, 2025, Ulta Beauty's CEO Kecia Steelman introduced us to the glamorous side of weight loss: hair loss and saggy skin. With roughly 10% of Americans now on GLP-1 drugs like Ozempic and Wegovy, folks aren’t just shrinking waistbands—they’re inflating Ulta’s sales. The beauty giant raked in $12.39 billion in 2025, boosted by a suspicious 11.8% sales jump and booming demand for hairfall fixes and skin elasticity potions. Meanwhile, Wall Street’s tailoring tailored their suits for smaller bodies and swiss pharma bosses laughed all the way to the bank with filler injections to fight the infamous 'Ozempic face'. All hail the new wellness economy, where rapid weight loss means rapid skin and hair treatments at your nearest Ulta.